H.C. Wainwright says the selloff yesterday in shares of Cardiff Oncology (CRDF) brings an attractive entry point. The firm finds updated CRDF-004 trial results “highly encouraging.” It expects a more mature clinical dataset from the CRDF-004 study in the first half of 2026. The market “overreaction provides an attractive entry point,” says H.C. Wainwright. The analyst keeps a Buy rating on Cardiff Oncology with a $10 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRDF:
- Cardiff Oncology Overhauls Leadership to Advance Onvansertib
- Balancing Leadership Turmoil and Focused Clinical Strategy: Maintaining a Buy on Cardiff Oncology’s Onvansertib Amid Catalyst-Rich Outlook
- Cardiff Oncology announces CEO Erlander, CFO Levine have stepped down
- Cardiff Oncology announces update from CRDF-004, Phase 2 trial of onvansertib
- Cardiff Oncology initiated with an Outperform at Noble Capital